Heart failure: A decision analytic analysis of New Zealand data using the published results of the SOLVD treatment trial

PharmacoEconomics

Volumn 9, Issue 2, 1996, Pages 156-167

  Scott, W Guy ^a,b   Scott, Helen M ^b  

^a Intl Ocean Inst Reg Ctr A   (New Zealand)

^b NONE   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; ENALAPRIL; FUROSEMIDE;

ARTICLE; CLINICAL TRIAL; COST CONTROL; COST EFFECTIVENESS ANALYSIS; DECISION THEORY; DRUG COST; HEALTH CARE COST; HEART FAILURE; HEART LEFT VENTRICLE FAILURE; HOSPITAL COST; HUMAN; MODEL; MORTALITY; NEW ZEALAND; PRIORITY JOURNAL; SURVIVAL;

EID: 0030033164     PISSN: 11707690     EISSN: None     Source Type: Journal    
DOI: 10.2165/00019053-199609020-00007     Document Type: Article

References (20)

1. van Hout BA, Wielink G, Bonsel GJ, et al. Effects of ACE inhibitors on heart failure in The Netherlands. Pharmaco-Economics 1993 May; 3 (5): 387-97
2. The SOLVD Investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med 1991; 325: 293-302
3. The CONSENSUS Trial Study Group. Effects of enalapril on mortality in severe congestive heart failure: results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). N Engl J Med 1987; 316: 1429-35
4. Cohn JN, Johnson G, Ziesche S, et al. A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure. (V-HeFT II). N Engl J Med 1991; 325: 303-10
5. International Classification of Diseases. 9th rev. ed. Clinical Modification (1CD-9CM). Ann Arbor (MI): WHO, 1978
6. Ministry of Health. Mortality and demographic data 1992. Wellington: Ministry of Health, 1994
7. Ministry of Health. Hospital and selected morbidity data 1992. Wellington: Ministry of Health, 1981-93
8. McKendry CG, Muthumala D. Health expenditure trends in New Zealand: update to 1993 [appendix 2A]. Wellington: Ministry of Health, 1994
9. Doughty R, Yee T, Sharpe N. et al. Hospital admissions and deaths due to congestive heart failure in New Zealand, 1988-1991. N Z Med J 1995; 108 (1012): 473-6
10. Wild CJ, Seber GAF. Introduction to probability and statistics. Auckland: Department of Statistics, Auckland University, 1995
11. Kannel WB, Belanger AJ. Epidemiology of heart failure. Am Heart J 1991; 121: 951-7
12. Schocken DD, Arrieta MI, Leaverton PE, et al. Prevalence and mortality rate of congestive heart failure in the United States. J Am Coll Cardiol 1992; 20: 301-6
13. Taylor Nelson Cardiomonitor - New Zealand, Autumn 1993. Epsom, Surrey: Taylor Nelson Healthcare, 1993
14. Pricing schedules: 1 September 1993. Wellington: Ministry of Health, 1993: 59
15. Core health and disability support services for 1993/94. First report of the National Advisory Committee on Core Health and Disability Support Services [appendix 6]. Wellington: National Advisory Committee on Core Health and Disability Support Services, 1992
16. Scott WG, Scott HM. Ischaemic stroke in New Zealand: an economic study. NZ Med J 1994; 107: 443-6
17. Scott WG, McKendry CG, Scott HM. Methodologies for economic evaluation of high technology in health care. Wellington: Department of Health, 1992
18. Scott WG, White HD, Scott HM. Cost of coronary heart disease in New Zealand. N Z Med J 1993; 106: 347-9
19. Wilde MI, Bryson HM, Goa KL. Enalapril: a review of quality-of-life and pharmacoeconomic aspects of its use in heart failure and mild to moderate hypertension. PharmacoEconomics 1994; 6: 155-82
20. Statistics New Zealand. Personal Computer Information Network for Official Statistics: a computerised database of official statistics for New Zealand and programme for manipulation and analysis of statistical series (PC INFOS). Wellington: Statistics New Zealand, 1993